Dr. George Carratalà leads a new research project on community-acquired pneumonia

Fourteen projects led by researchers at the University Hospital of Bellvitge (from a total of 27 projects from IDIBELL researchers) have received funding from the health research program of  the Fondo de Investigación Sanitaria (FIS) in 2011 .

The works funded are established translational health research group projects a with a length of four years, or general research projects with a length of three years.  To see a list of these projects, click here .

Dr. Jordi Carratalà, medical coordinator of Infectious Diseases is the main investigator of the project entitled usefulness of a PIRO scale-based model to classify hospitalized adults in community acquired Pneumonia depending on the immune answer and prognosis . It was funded with € 132,000 and will be developed primarily by specialists of the Department of Infectious Diseases, in collaboration with specialists in Respiratory Medicine, Microbiology and Immunology of our center.

It is one of four projects of the Department of Infectious Disease funded this year by the FIS. In the last years this service has achieved funding for 7 projects for a total of 650,000 €.

The Hub began its line of research in community-acquired pneumonia in 1995, since then more than 4,600 patients have been treated and followed up. The funding for research in this area resulted in numerous publications in various prestigious scientific journals. Many results have been incorporated in international clinical practice guidelines and have helped change standards of  patient treatment.

However, pneumonia in the community still has a significant mortality (8%), not decreasing despite advances in antibiotic treatment. This is mainly related to the inadequate inflammatory response of the patient. It has, therefore generated an interest to know more deeply the inflammatory response, which would  result in  a better modulation  by drug administration.

The study will analyze a PIRO scale based model that incorporates four types of variables ( willingness and comorbidity, nature of the infection, host response, and extent of organ dysfunction). In this sense, there will be a series of determinations of cytokines and inflammatory markers, from a large cohort of patients. The processing and final analysis of the data will determine the effectiveness of the scale when classifying patients who require admission by the immune response and prognosis, and identify those patients susceptible of modulation of the Inflammatory response.

Notícies relacionades |Noticias relacionadas | Related news

Comments are closed.

Home | eHub | Email